Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 11;15(1):57.
doi: 10.1186/s13045-022-01281-9.

Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis

Junjie Huang  1 , Wing Sze Pang  1 , Veeleah Lok  2 , Lin Zhang  3   4 , Don Eliseo Lucero-Prisno 3rd  5 , Wanghong Xu  6 , Zhi-Jie Zheng  7 , Edmar Elcarte  8 , Mellissa Withers  9 , Martin C S Wong  10   11   12 ; NCD Global Health Research Group, Association of Pacific Rim Universities (APRU)
Affiliations

Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis

Junjie Huang et al. J Hematol Oncol. .

Abstract

Background: Hodgkin lymphoma is a lymphatic malignancy commonly found in cervical lymph nodes. This study evaluated the worldwide incidence, mortality, associated risk factors, and temporal trends of Hodgkin lymphoma by sex, age, and country.

Methods: The age-standardised Hodgkin lymphoma incidence and mortality were retrieved from the GLOBOCAN, CI5 volumes I-XI, WHO mortality database, the NORDCAN and SEER Program. The age-standardised prevalence of smoking, alcohol drinking, obesity, and hypertension was also extracted for each country. Trends were tested using Average Annual Percentage Change (AAPC) from Joinpoint regression analysis.

Results: The Hodgkin lymphoma incidence and mortality were 0.98 and 0.26 per 100,000 in 2020. A higher incidence was observed in high-income countries, while higher mortality was found in low-income countries. Incidence and mortality were associated with GDP per capita, prevalence of smoking, obesity, and hypertension at the population level. Despite the decreasing mortality trend, there was an increasing incidence, especially among females, younger population, and subjects from Asian countries.

Conclusions: There was an increasing trend in Hodgkin lymphoma incidence, especially among subjects who were female, younger population, and from Asian countries. Further studies are needed to investigate the reasons for these epidemiologic trends.

Keywords: Hodgkin lymphoma; Incidence; Mortality; Risk factors; Temporal trend.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Global incidence and mortality of Hodgkin lymphoma, both sexes, all ages, in 2020
Fig. 2
Fig. 2
Associations between risk factors and Hodgkin lymphoma incidence
Fig. 3
Fig. 3
Associations between risk factors and Hodgkin lymphoma mortality
Fig. 4
Fig. 4
AAPC of Hodgkin lymphoma incidence in individuals aged 0–85+ years old
Fig. 5
Fig. 5
AAPC of Hodgkin lymphoma mortality in individuals aged 0–85+ years old
See this image and copyright information in PMC

References

    1. Kaseb H, Babiker HM. Hodgkin lymphoma. Updated June 30, 2021. Accessed 21 Feb 2022. https://www.ncbi.nlm.nih.gov/books/NBK499969/.
    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):30–44. doi: 10.1016/j.semradonc.2009.09.006. - DOI - PubMed
    1. Metzger ML, Mauz-Körholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol. 2019;185(6):1142–1157. doi: 10.1111/bjh.15789. - DOI - PubMed
    1. Amraee A, Evazi MR, Shakeri M, et al. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study. Clin Transl Oncol. 2019;21(8):1093–1103. doi: 10.1007/s12094-018-02032-4. - DOI - PubMed